Clozapine-associated neutropenia and agranulocytosis in Argentina (2007-2012).

Balda MV, Garay OU, Papale RM, Bignone I, Bologna VG, Brandolini A, et al. Clozapine-associated neutropenia and agranulocytosis in Argentina (2007-2012). Int Clin Psychopharmacol. 2015;30(2):109-14. DOI: 10.1097/YIC.0000000000000060. PubMed PMID: 25486383.

Practical guidelines for the use of new generation antipsychotic drugs (except clozapine) in adult individuals with intellectual disabilities.

de Leon J, Greenlee B, Barber J, Sabaawi M, Singh NN. Practical guidelines for the use of new generation antipsychotic drugs (except clozapine) in adult individuals with intellectual disabilities. Res Dev Disabil. 2009;30(4):613-69. DOI: 10.1016/j.ridd.2008.10.010. PubMed PMID: 19084370.

Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week randomized, double-blind, placebo-controlled trial.

Joffe G, Takala P, Tchoukhine E, Hakko H, Raidma M, Putkonen H, et al. Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2008;69(5):706-11. PubMed PMID: 18426261.

Medical management of patients on clozapine: A guide for internists.

Lundblad W, Azzam PN, Gopalan P, Ross CA. Medical management of patients on clozapine: A guide for internists. J Hosp Med. 2015;10(8):537-43. DOI: 10.1002/jhm.2345. PubMed PMID: 25809850.

Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis.

Samara MT, Dold M, Gianatsi M, Nikolakopoulou A, Helfer B, Salanti G, et al. Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis. Jama Psychiatry. 2016;73(3):199-210. DOI: 10.1001/jamapsychiatry.2015.2955. PubMed PMID: 26842482.

Risk of venous thromboembolism due to antipsychotic drug therapy.

Hägg S, Jönsson AK, Spigset O. Risk of venous thromboembolism due to antipsychotic drug therapy. Expert Opin Drug Saf. 2009;8(5):537-47. DOI: 10.1517/14740330903117271. PubMed PMID: 19569978.

Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications.

Leslie DL, Rosenheck RA. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry. 2004;161(9):1709-11. DOI: 10.1176/appi.ajp.161.9.1709. PubMed PMID: 15337666.

Life-Threatening Lupus-Like Syndrome Associated With Clozapine.

Buzina N, Eterović M. Life-Threatening Lupus-Like Syndrome Associated With Clozapine. J Clin Psychopharmacol. 2016;36(5):532-4. DOI: 10.1097/JCP.0000000000000550. PubMed PMID: 27580496.

Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine.

Conley RR, Love RC, Kelly DL, Bartko JJ. Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine. AJP. 1999;156(6):863-8. DOI: 10.1176/ajp.156.6.863. PubMed PMID: 10360124.

Time to rehospitalization in patients with schizophrenia discharged on first generation antipsychotics, non-clozapine second generation antipsychotics, or clozapine.

Werneck AP, Hallak JC, Nakano E, Elkis H. Time to rehospitalization in patients with schizophrenia discharged on first generation antipsychotics, non-clozapine second generation antipsychotics, or clozapine. Psychiatry Res. 2011;188(3):315-9. DOI: 10.1016/j.psychres.2011.04.004. PubMed PMID: 21596442.